[PDF][PDF] 930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Open Forum …, 2023 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) protects against severe outcomes after
SARS-CoV-2 (SCV2) infection, but patients and studies have described symptom and viral …
SARS-CoV-2 (SCV2) infection, but patients and studies have described symptom and viral …
930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not taking …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Open Forum …, 2023 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) protects against severe outcomes after
SARS-CoV-2 (SCV2) infection, but patients and studies have described symptom and viral …
SARS-CoV-2 (SCV2) infection, but patients and studies have described symptom and viral …
930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not taking …
Open Forum Infectious Diseases, 2023 - europepmc.org
Background Nirmatrelvir/ritonavir (N/R) protects against severe outcomes after SARS-CoV-2
(SCV2) infection, but patients and studies have described symptom and viral rebound after …
(SCV2) infection, but patients and studies have described symptom and viral rebound after …
[HTML][HTML] 930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Open Forum …, 2023 - ncbi.nlm.nih.gov
Background Nirmatrelvir/ritonavir (N/R) protects against severe outcomes after SARS-CoV-2
(SCV2) infection, but patients and studies have described symptom and viral rebound after …
(SCV2) infection, but patients and studies have described symptom and viral rebound after …